🔎 Trials Near Me

Hjem › Myelofibrose › New York

Myelofibrose kliniske forsøg i New York

21 studier for Myelofibrose søger deltagere på steder i New York.

Byer i New York

Officiel studietekst (engelsk)

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

  • Icahn School of Medicine at Mount Sinai, New York
  • Memorial Sloan Kettering Cancer Center, New York
  • Weill Cornell Medical Center, New York
  • og 1 flere
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04176198

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  • New York Oncology Hematology P C, Albany
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07357727

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  • Memorial Sloan Kettering Cancer Center, New York
  • Icahn School of Medicine at Mount Sinai, New York
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07623161

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

  • NYP/Weill Cornell Medical Center, New York
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT06661915

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

  • Memorial Sloan Kettering Cancer Center, New York
  • Icahn School of Medicine at Mount Sinai, New York
  • Montefiore, New York
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT05320198

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering, New York
  • Icahn School of Medicine at Mount Sinai, New York
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT06343805

A Telehealth Advance Care Planning Intervention

  • University of Rochester, Rochester
Rekrutterer
Alder 60 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT05875805

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

  • Icahn School of Medicine At Mount Sinai, New York
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 6. aug. 2026 · NCT07008118

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
  • Memorial Sloan Kettering Cancer Center, New York
  • og 1 flere
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. jul. 2026 · NCT06773195

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  • Memorial Sloan Kettering Cancer Center, New York
  • Mount Sinai School of Medicine, New York
  • Weill Cornell Medicine, New York
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. jul. 2026 · NCT07441694

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

  • Wilmot Cancer Institute, University of Rochester, Rochester
RekruttererTidlig fase 1
Alder 18 til 75 · Alle køn · Opdateret 3. jun. 2026 · NCT03964506

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

  • Roswell Park Cancer Institute, Buffalo
  • Ruttenberg Treatment Center, New York
  • Memorial Sloan Kettering Cancer Center, New York
  • og 1 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 6. maj 2026 · NCT05835466

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

  • GSK Investigational Site, New York
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 20. apr. 2026 · NCT06517875

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  • Icahn School of Medicine At Mount Sinai, New York
  • Memorial Sloan Kettering Cancer Center, New York
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 17. apr. 2026 · NCT06034002

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

  • Weill Cornell Medicine NewYork-Presbyterian, New York
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 12. feb. 2026 · NCT05980806

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

  • Memorial Sloan Kettering Cancer Center, New York
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 23. jan. 2026 · NCT07362225

MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial

  • Ruttenberg Treatment Center, New York
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 17. dec. 2025 · NCT06541249

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Buffalo
  • Massive Bio SYNERGY-AI site, Hempstead
  • Massive Bio SYNERGY-AI site, Manhasset
  • og 2 flere
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  • Brookdale University Hospital and Medical Center, Brooklyn
  • Cayuga Cancer Center, Ithaca
  • Northwell Health, R.J. Zuckerberg Cancer Center, Lake Success
  • og 2 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2025 · NCT06479135

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

  • Columbia University, New York
  • Montefiore Einstein Cancer Center, The Bronx
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. apr. 2025 · NCT05423691

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.